Analysis of China's market of lipid-lowering drugs from 2013 to 2016
-
Last Update: 2017-12-28
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Wonderful content according to the 2016 edition of China's guidelines for the prevention and treatment of adult dyslipidemia, China's cardiovascular events will increase by about 9.2 million in 2010-2030, and the overall prevalence of adult dyslipidemia is as high as 40.4% Dyslipidemia is a long-term chronic disease under the influence of various factors Although there are no obvious symptoms, there are still 50% cases of arteriosclerosis and vascular plaque in the elderly If the management is not strengthened, it will lead to a major disaster The market scale of lipid-lowering drugs in China has continued to grow According to the data of mienei.com, the total sales volume of public hospitals in cities, county-level public hospitals, urban community centers and township hospitals reached 20.6 billion yuan in 2016 Author: Wei Xi drawing: fengmanlou
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
